Phase 1b/2 trial in women with persistent high-risk HPV and low-grade cervical lesions: VTP-200 was well tolerated and immunogenic, but secondary-outcome HPV clearance did not differ from placebo (31.3% vs 33.3%), nor did lesion clearance.
RCTn = 108
Hellner et al. A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions